Zealand Pharma to delist in US
The Danish biotech company informs US investors that trading of its American depositary shares will cease in November.
by marketwire, translated by daniel pedersen
Zealand Pharma is returning exclusively to the stock exchange in Denmark, and on Monday, the Danish biotech company informed holders of its American depositary shares (ADS) that it intends to delist from the New York-based Nasdaq Global Select Market in the US, according to a press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Zealand Pharma hires head of regulatory affairs
For subscribers
Zealand Pharma enters AI partnership with Iktos
For subscribers
Lundbeck to delist in US
For subscribers
